Development of Breast Cancer Risk Model Based on Estrogen Metabolomics

基于雌激素代谢组学的乳腺癌风险模型的开发

基本信息

  • 批准号:
    8550778
  • 负责人:
  • 金额:
    $ 33.58万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-09-25 至 2014-08-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Development of breast cancer risk model based on estrogen metabolomics. Anti-estrogens provide an effective strategy to prevent breast cancer but eligible women generally decline therapy because of unfavorable benefit/risk ratios. Data from prevention studies indicate that fifty women need to be treated with these agents for five years to prevent one breast cancer. To improve the ratio of benefit to risk, a more powerful method of identifying women at very high risk of developing breast cancer is urgently needed. Prediction of disease risk is best grounded on factors involved in its pathogenesis. We propose an integrative hypothesis regarding the carcinogenic process which involves both estrogen receptor alpha (ER¿) dependent as well as ER¿ independent actions. Through ER¿, estradiol (E2) stimulates proliferation with resultant replicative mutations and promotes the growth of cells harboring those mutations. Independent of ER¿, estrogen metabolites both form unstable DNA adducts and generate oxygen free radicals thorough redox cycling to initiate mutations. Several genetically regulated enzymes modulate estrogen metabolism and the process of repair of estrogen induced mutations. Our innovative hypothesis regarding estrogen induced breast cancer integrates all of these processes into a model of carcinogenesis and implicates the entire estrogen metabolome in the genesis of breast cancer. These concepts suggest that measurement of estrogen metabolomics should provide a powerful, mechanism-based method of predicting who will develop breast cancer. Metabolomic assessment entails quantitative measurement of aromatizable androgens, estrogens, and their metabolites and SNPs from enzymes regulating the metabolic process. Several important factors have recently come together to enable us to test this concept. A new, state of the art, mass spectrometer coupled with an ultra-performance liquid chromatography system makes it possible for the first time to measure all estrogen metabolites in small amounts of serum. We can measure SNPs which involve enzymes regulating estrogen metabolism and have been shown to correlate with breast cancer risk. To develop a model, we will utilize serum samples and risk factor data from 3 cohort studies (NYU, Clue I and II, and Rancho Bernardo) which had collected blood from women 5-20 years ago and then followed them prospectively for development of breast cancer. Availability of these techniques, samples and risk factor data allows performance of a nested case-control study to develop a new, more powerful risk prediction model. We will then validate this model in a completely independent data set involving the French Teacher's Study. We anticipate reducing the number of women needed to be treated to prevent one breast cancer from 50 to 13 with tamoxifen and to 5.with aromatase inhibitors.
描述(申请人提供):基于雌激素代谢组学的乳腺癌风险模型的发展。抗雌激素为预防乳腺癌提供了一种有效的策略,但符合条件的女性通常会因为不利的益处/风险比而拒绝治疗。来自预防研究的数据表明,50名妇女需要接受这些药物为期5年的治疗才能预防一例乳腺癌。为了提高受益与风险的比率,迫切需要一种更有效的方法来识别罹患乳腺癌风险极高的妇女。对疾病风险的预测最好基于其发病机制中涉及的因素。我们提出了一个关于致癌过程的综合假说,该过程既涉及雌激素受体α(ER?)依赖的作用,也涉及ER?非依赖性的作用。雌二醇(E_2)通过ER?刺激细胞增殖,产生复制突变,促进细胞生长 藏匿着这些突变。雌激素代谢产物不依赖内质网,形成不稳定的DNA加合物,并通过氧化还原循环产生氧自由基,从而引发突变。几种受基因调控的酶调节雌激素代谢和雌激素诱导突变的修复过程。我们关于雌激素诱导乳腺癌的创新假说将所有这些过程整合到一个致癌模型中,并将整个雌激素代谢组与乳腺癌的发生联系起来。这些概念表明,雌激素代谢组学的测量应该提供一种强大的、基于机制的方法来预测谁会患乳腺癌。代谢组学评估需要定量测量可芳香化的雄激素、雌激素及其代谢物和调节代谢过程的酶的SNPs。最近,几个重要因素结合在一起,使我们能够测试这一概念。一种新的、最先进的质谱仪与超高效液相色谱系统相结合,首次使测定少量血清中的所有雌激素代谢物成为可能。我们可以测量SNPs,它涉及调节雌激素新陈代谢的酶,并已被证明与乳腺癌风险相关。为了建立一个模型,我们将利用3项队列研究(纽约大学、线索I和线索II以及兰乔·贝尔纳多)的血清样本和危险因素数据,这些研究在5-20年前采集了女性的血液,然后前瞻性地跟踪了她们患乳腺癌的情况。这些技术、样本和风险因素数据的可获得性使嵌套病例对照研究能够开发出新的、更强大的风险预测模型。然后,我们将在一个完全独立的数据集中验证这个模型,该数据集涉及这位法语教师的研究。我们预计,使用他莫昔芬可以将预防一例乳腺癌所需治疗的女性人数从50人减少到13人,使用芳香酶抑制剂则可以减少到5人。

项目成果

期刊论文数量(5)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Ultrasensitive quantification of serum estrogens in postmenopausal women and older men by liquid chromatography-tandem mass spectrometry.
  • DOI:
    10.1016/j.steroids.2015.01.014
  • 发表时间:
    2015-04
  • 期刊:
  • 影响因子:
    2.7
  • 作者:
    Wang Q;Rangiah K;Mesaros C;Snyder NW;Vachani A;Song H;Blair IA
  • 通讯作者:
    Blair IA
Cellular uptake and antiproliferative effects of 11-oxo-eicosatetraenoic acid.
  • DOI:
    10.1194/jlr.m040741
  • 发表时间:
    2013-11
  • 期刊:
  • 影响因子:
    6.5
  • 作者:
    Snyder NW;Revello SD;Liu X;Zhang S;Blair IA
  • 通讯作者:
    Blair IA
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Ian Alexander Blair其他文献

Ian Alexander Blair的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Ian Alexander Blair', 18)}}的其他基金

Melanoma: Metabolic Biomarkers of Response to Targeted Therapy
黑色素瘤:靶向治疗反应的代谢生物标志物
  • 批准号:
    10337249
  • 财政年份:
    2020
  • 资助金额:
    $ 33.58万
  • 项目类别:
Melanoma: Metabolic Biomarkers of Response to Targeted Therapy
黑色素瘤:靶向治疗反应的代谢生物标志物
  • 批准号:
    10115684
  • 财政年份:
    2020
  • 资助金额:
    $ 33.58万
  • 项目类别:
Melanoma: Metabolic Biomarkers of Response to Targeted Therapy
黑色素瘤:靶向治疗反应的代谢生物标志物
  • 批准号:
    10565951
  • 财政年份:
    2020
  • 资助金额:
    $ 33.58万
  • 项目类别:
Analytical validation of frataxin proteoforms in blood as biomarkers of Friedreich's ataxia
血液中 frataxin 蛋白质形式作为弗里德赖希共济失调生物标志物的分析验证
  • 批准号:
    10356088
  • 财政年份:
    2020
  • 资助金额:
    $ 33.58万
  • 项目类别:
Analytical validation of frataxin proteoforms in blood as biomarkers of Friedreich's ataxia
血液中 frataxin 蛋白质形式作为弗里德赖希共济失调生物标志物的分析验证
  • 批准号:
    10582596
  • 财政年份:
    2020
  • 资助金额:
    $ 33.58万
  • 项目类别:
Analytical validation of frataxin proteoforms in blood as biomarkers of Friedreich's ataxia
血液中 frataxin 蛋白质形式作为弗里德赖希共济失调生物标志物的分析验证
  • 批准号:
    10117295
  • 财政年份:
    2020
  • 资助金额:
    $ 33.58万
  • 项目类别:
Asbestos fate, exposure, remediation, and adverse health effects
石棉的归宿、接触、修复和不良健康影响
  • 批准号:
    9530878
  • 财政年份:
    2014
  • 资助金额:
    $ 33.58万
  • 项目类别:
Asbestos fate, exposure, remediation, and adverse health effects
石棉的归宿、接触、修复和不良健康影响
  • 批准号:
    9041609
  • 财政年份:
    2014
  • 资助金额:
    $ 33.58万
  • 项目类别:
Asbestos fate, exposure, remediation, and adverse health effects
石棉的归宿、接触、修复和不良健康影响
  • 批准号:
    8651082
  • 财政年份:
    2014
  • 资助金额:
    $ 33.58万
  • 项目类别:
Core N: MOLECULAR PROFILING
核心 N:分子谱分析
  • 批准号:
    8126787
  • 财政年份:
    2012
  • 资助金额:
    $ 33.58万
  • 项目类别:

相似海外基金

Collaborative Research: REU Site: Earth and Planetary Science and Astrophysics REU at the American Museum of Natural History in Collaboration with the City University of New York
合作研究:REU 地点:地球与行星科学和天体物理学 REU 与纽约市立大学合作,位于美国自然历史博物馆
  • 批准号:
    2348998
  • 财政年份:
    2025
  • 资助金额:
    $ 33.58万
  • 项目类别:
    Standard Grant
Collaborative Research: REU Site: Earth and Planetary Science and Astrophysics REU at the American Museum of Natural History in Collaboration with the City University of New York
合作研究:REU 地点:地球与行星科学和天体物理学 REU 与纽约市立大学合作,位于美国自然历史博物馆
  • 批准号:
    2348999
  • 财政年份:
    2025
  • 资助金额:
    $ 33.58万
  • 项目类别:
    Standard Grant
Collaborative Research: Ionospheric Density Response to American Solar Eclipses Using Coordinated Radio Observations with Modeling Support
合作研究:利用协调射电观测和建模支持对美国日食的电离层密度响应
  • 批准号:
    2412294
  • 财政年份:
    2024
  • 资助金额:
    $ 33.58万
  • 项目类别:
    Standard Grant
Conference: Doctoral Consortium at Student Research Workshop at the Annual Conference of the North American Chapter of the Association for Computational Linguistics (NAACL)
会议:计算语言学协会 (NAACL) 北美分会年会学生研究研讨会上的博士联盟
  • 批准号:
    2415059
  • 财政年份:
    2024
  • 资助金额:
    $ 33.58万
  • 项目类别:
    Standard Grant
Conference: Polymeric Materials: Science and Engineering Division Centennial Celebration at the Spring 2024 American Chemical Society Meeting
会议:高分子材料:美国化学会 2024 年春季会议科学与工程部百年庆典
  • 批准号:
    2415569
  • 财政年份:
    2024
  • 资助金额:
    $ 33.58万
  • 项目类别:
    Standard Grant
Collaborative Research: RUI: Continental-Scale Study of Jura-Cretaceous Basins and Melanges along the Backbone of the North American Cordillera-A Test of Mesozoic Subduction Models
合作研究:RUI:北美科迪勒拉山脊沿线汝拉-白垩纪盆地和混杂岩的大陆尺度研究——中生代俯冲模型的检验
  • 批准号:
    2346565
  • 财政年份:
    2024
  • 资助金额:
    $ 33.58万
  • 项目类别:
    Standard Grant
REU Site: Research Experiences for American Leadership of Industry with Zero Emissions by 2050 (REALIZE-2050)
REU 网站:2050 年美国零排放工业领先地位的研究经验 (REALIZE-2050)
  • 批准号:
    2349580
  • 财政年份:
    2024
  • 资助金额:
    $ 33.58万
  • 项目类别:
    Standard Grant
Collaborative Research: RUI: Continental-Scale Study of Jura-Cretaceous Basins and Melanges along the Backbone of the North American Cordillera-A Test of Mesozoic Subduction Models
合作研究:RUI:北美科迪勒拉山脊沿线汝拉-白垩纪盆地和混杂岩的大陆尺度研究——中生代俯冲模型的检验
  • 批准号:
    2346564
  • 财政年份:
    2024
  • 资助金额:
    $ 33.58万
  • 项目类别:
    Standard Grant
Conference: Latin American School of Algebraic Geometry
会议:拉丁美洲代数几何学院
  • 批准号:
    2401164
  • 财政年份:
    2024
  • 资助金额:
    $ 33.58万
  • 项目类别:
    Standard Grant
Conference: North American High Order Methods Con (NAHOMCon)
会议:北美高阶方法大会 (NAHOMCon)
  • 批准号:
    2333724
  • 财政年份:
    2024
  • 资助金额:
    $ 33.58万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了